Sun, Apr 20, 2014, 7:39 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Array BioPharma, Inc. Message Board

  • dcaf7 dcaf7 Mar 29, 2013 12:24 PM Flag

    New phase 2 study with MEK 162 by Novartis

    LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma (LOGIC)

    Detailed Description:

    This is a phase II two part multi-center, open-label study. Part I: LGX818 single agent treatment until progression Part II: Combination treatments of LGX818 + MEK162, or BKM120, or BGJ398, or INC280, or LEE01 to assess the clinical efficacy, to further evaluate the safety of the drug combinations in patients with locally advanced or metastatic BRAF mutant melanoma after relapse on LGX818, and to determine the maximum tolerated dose of the combinations (when not established previously). These drug combinations are selected and assigned to patients based on documentation of molecular resistance mechanism.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ARRY
3.79-0.05(-1.30%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
AsiaInfo-Linkage, Inc.
NasdaqGSWed, Jan 15, 2014 4:00 PM EST